Table 2Sensitivity analysis for KQ 6

OutcomeMeta-analysisContinuity correctionEffect estimate and 95% CIEffect estimate and 95% CI (Stata)Statistical heterogeneityStatistical heterogeneity (Stata)
PE1-5RR Random effects0.11.30 (95% CI = 0.57 to 3.01)1.30 (95% CI = 0.57 to 3.01)11.2%11.2%
RR Random effects0.51.16 (95% CI = 0.51 to 2.66)1.17 (95% CI = 0.51 to 2.67)16.0%16.0%
RR Random effectsTreatment arm1.21 (95% CI = 0.57 to 2.56)1.21 (95% CI = 0.57 to 2.56)6.9%6.9%
Peto ORNo CC0.99 (95% CI = 0.49 to 2.00)0.99 (95% CI = 0.49 to 1.96)36.2%36.2%
Mortality1-4RR Random effects0.15.95 (95% CI = 1.99 to 17.81)5.95 (95% CI = 1.99 to 17.81) *0%0%
RR Random effects0.54.45 (95% CI = 1.55 to 12.72)4.45 (95% CI = 1.55 to 12.72) *4.1%4.1%
RR Random effectsTreatment arm4.30 (95% CI = 1.60 to 11.54)4.30 (95% CI = 1.60 to 11.54) *0%0%
Peto ORNo CC3.87 (95% CI = 1.32 to 11.35) *3.87 (95% CI = 1.32 to 11.35) *70.5%70.5%
DVT1 3-5RR Random effects0.12.94 (95% CI = 1.35 to 6.38)2.93 (95% CI = 1.35 to 6.38) *40.3%42.2%
RR Random effects0.52.94 (95% CI = 1.35 to 6.38)3.13 (95% CI = 1.39 to 7.06) *40.3%40.3%
RR Random effectsTreatment arm2.94 (95% CI = 1.35 to 6.38)2.93 (95% CI = 1.35 to 6.38) *40.3%40.3%
Peto ORNo CC2.93 (95% CI = 1.49 to 5.78) *2.93 (95% CI = 1.49 to 5.78) *78%78%
*

Statistically significant

From: Appendix H, Sensitivity Analysis for KQ 1 and KQ 6

Cover of Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations
Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet].
Comparative Effectiveness Reviews, No. 116.
Singh S, Haut ER, Brotman DJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.